PubMed Health⌕ Search

Biomedical subjects

John S James

Publications and source records attributed to John S James.

At least 19 recordsLinked to original sources

Funding alert: wake up and support WORLD.

As governments cut back, the AIDS community must fund information and advocacy or lose control of its future. We need activists who can be credible with both service providers and donors, and serve as diplomats between them.

Drug Industry↗

Huge price variations in generic drugs.

Huge, secret price variations create huge profits for the well connected, raising prices for patients and the public. One drug with an "average wholesale price" of $2.66 per pill was actually sold to pharmacies for 5 cents per pill.

Drug Costs↗

SARS Web information.

Where to find current information about Severe Acute Respiratory Syndrome (SARS), a new disease that can cause severe or fatal pneumonia.

Hong Kong↗

Abacavir arm stopped in clinical trial.

A government clinical trial stopped treatment with abacavir plus AZT plus 3TC, due to more viral rebound than other treatments in the study. Many unknowns remain.

Anti-HIV Agents↗

Huge Medicaid cuts weighed in Washington.

A $92 billion Medicaid cut passed by the U.S. House of Representatives, and a plan by the Bush Administration to reduce entitlement funding of medical care for the poor and elderly and give states more power to choose whose benefits are ended, could seriously reduce HIV care in the coming decade.

Budgets↗

Building grassroots support for AIDS.

Citizen-action campaigns (like getting people to call Congress or their state representatives to support Medicaid, ADAP, or other program for access to medical care) could get much more response if they were made accessible to the millions of people who are already supportive but not already involved. We suggest several ways to make action alerts and other citizen organizing work better.

Acquired Immunodeficiency Syndrome↗

Bush proposes near tripling of U.S. commitment on global HIV epidemic.

The presidential initiative to increase funding for global AIDS prevention and treatment is widely seen as a groundbreaking advance. But critical time will be lost if the U.S. focuses so heavily on building its own new system, instead of using multinational organizations like the Global Fund that are ready now.

Budgets↗

U.S. blocks trade agreement on generic drug access in poor countries.

Governments can override patents for legitimate purposes, including public health. But many small or poor countries hve no pharmaceutical industry to manufacture medicines themselves, and global trade rules being phased in will prevent others from exporting to them without the patent holder's permission. Negotiations to solve this problem broke down when the U.S. insisted that any agreement apply only to AIDS, tuberculosis, malaria, and similar major epidemics--excluding cancer, heart disease, and hundreds of other diseases.

Commerce↗